Study investigator, Dr. Jeffrey Neul, is featured today on NeurologyLive, discussing trofinetide as a potential treatment for Rett syndrome.
NeurologyLive is a media platform for healthcare professionals treating neurological diseases.Dr. Neul points out that, not only is Lavender the first Phase 3 study that has met primary endpoints in Rett syndrome, but it is also one of the first times a successful phase 3 trial has been completed in any neurodevelopmental disorder.
https://www.neurologylive.com/view/trofinetide-as-an-option-rett-syndrome-treatment
Ann: Rett Syndrome NDA accepted for Priority Review by FDA, page-20
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$16.15 |
Change
-0.940(5.50%) |
Mkt cap ! $2.064B | |||
| Open | High | Low | Value | Volume |
| $15.04 | $16.33 | $14.65 | $25.91M | 1.638M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 125 | $16.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.20 | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |